Shandong Ruiyi Pharmaceutical

Shandong Ruiyi Pharmaceutical is a Chinese biotechnology company focused on the research and development of innovative small molecule drugs, particularly in the metabolic and endocrine therapeutic areas. The company specializes in developing next-generation oral treatments for conditions such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Their primary research efforts center on multi-agonist small molecules targeting the GLP-1, GIP, and glucagon receptors to provide more convenient and effective alternatives to injectable biologics. Shandong Ruiyi operates out of the Jinan Innovation Zone, leveraging local pharmaceutical infrastructure to advance its early-stage pipeline.